Menu
Search
|

Menu

Close
X

Vericel Corp VCEL.OQ (NASDAQ Stock Exchange Capital Market)

7.25 USD
-- (--)
As of Feb 17
chart
Previous Close 7.25
Open --
Volume --
3m Avg Volume 97,427
Today’s High --
Today’s Low --
52 Week High 8.20
52 Week Low 2.35
Shares Outstanding (mil) 32.82
Market Capitalization (mil) 160.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
26
FY16
54
FY15
51
EPS (USD)
FY17
-0.379
FY16
-1.172
FY15
-0.971
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.99
5.77
Price to Book (MRQ)
vs sector
11.49
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
72.73
16.52
LT Debt to Equity (MRQ)
vs sector
57.62
12.22
Return on Investment (TTM)
vs sector
-120.46
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Robert Zerbe
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Dominick Colangelo
President, Chief Executive Officer, Director, Since 2014
Salary: $430,000.00
Bonus: $89,583.00
Gerard Michel
Chief Financial Officer, Vice President - Corporate Development, Since 2014
Salary: $204,167.00
Bonus: --
Daniel Orlando
Chief Operating Officer, Chief Commercial Officer, Since 2013
Salary: $292,125.00
Bonus: $45,600.00
Ross Tubo
Chief Scientific Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

64 Sidney St
CAMBRIDGE   MA   02139-4170

Phone: +1734.9305555

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

SPONSORED STORIES